Healthcare Industry News: bivalirudin
News Release - February 4, 2008
Steven Steinhubl, MD, Joins The Medicines Company as Global Vice President, ThrombosisPARSIPPANY, N.J.--(HSMN NewsFeed)--The Medicines Company (NASDAQ: MDCO ) today announced that Dr. Steven Steinhubl has joined the Company as Global Vice President, Thrombosis. Dr. Steinhubl will be responsible for the development programs for both cangrelor, an investigational antiplatelet agent, and Angiox® (bivalirudin) from the Company’s European headquarters in Zurich, Switzerland. His appointment marks the Company’s first global leadership position based outside of the United States.
“It is exciting to be a part of driving The Medicines Company’s growth into a global organization,” said Dr. Steinhubl. “Despite all the advances in acute care for heart disease, we still have a critical need to further improve outcomes for these patients. My experience as a clinician and cardiovascular researcher provides me with unique understanding to oversee development of cangrelor and other important therapies that can address the needs of acute cardiac care patients.”
Dr. Steinhubl is a leading interventional cardiologist and cardiovascular researcher. Prior to joining the Company, Dr. Steinhubl was an Associate Professor of Medicine and the Director of the Cardiovascular Education and Clinical Research at the University of Kentucky in Lexington for the past 4 years. Dr. Steinhubl has been the principle investigator and served on the Steering Committees for numerous large clinical trials including CREDO, STEEPLE, STRADIVARIUS, SYNERGY, and CHARISMA. His research activities have led to the publication of over 100 peer-reviewed manuscripts as well as numerous book chapters, and abstracts.
“Dr. Steinhubl’s real-world experience in acute cardiac care and international study experience will be invaluable to ensure we fully maximize the development programs for cangrelor and Angiox globally,” said Clive Meanwell, Chairman and CEO of The Medicines Company.
About The Medicines Company
The Medicines Company (NASDAQ: MDCO ) is committed to delivering innovative, cost-effective acute care products in the worldwide hospital marketplace. The Company markets Angiomax® / Angiox® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Company also has two products in late-stage development, CleviprexTM (clevidipine butyrate injectable emulsion) and cangrelor. The Company's website is www.themedicinescompany.com.
Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether clinical trial results will warrant submission of applications for regulatory approval, whether the Company will be able to obtain regulatory approvals, whether physicians, patients and other key decision-makers will accept clinical trial results, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on November 8, 2007, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.
Source: The Medicines Company
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.